Callio Therapeutics Secures $187 Million Series A for Cancer Treatment Innovation
Callio Therapeutics Secures $187 Million Series A for Cancer Treatment Innovation
SEATTLE and SINGAPORE, March 3, 2025 – Callio Therapeutics, a pioneering biotechnology company, has announced the successful closure of a Series A funding round, raising $187 million. This funding round was spearheaded by Frazier Life Sciences, with significant contributions from Jeito Capital and other prominent life sciences investors including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital, and EDBI. Callio is set to channel this funding towards advancing clinical proof-of-concept for its innovative multi-payload antibody-drug conjugate (ADC) platform.
The company's technology aims to overcome the limitations of existing single-payload therapies, providing a more effective treatment option for cancer patients. The funds will primarily be utilized for a dual payload ADC targeting HER2 and another, yet undisclosed ADC program.
In conjunction with this funding, Callio has established an exclusive global licensing agreement with Hummingbird Bioscience for their multi-payload ADC platform in oncology, encompassing valuable IP and pipeline assets. Dr. Piers Ingram, co-founder and CEO of Callio Therapeutics, expressed excitement about the firm’s direction, stating, “Multi-Payload ADCs hold remarkable potential by enabling the rational delivery of drug combinations directly to cancer cells, thereby leading to significantly enhanced efficacy.”
Leadership and Expertise
Callio Therapeutics is led by a highly experienced team with backgrounds in leading biotechnological and biopharma companies, such as ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, Hummingbird Bioscience, and Genentech. The team includes:
- - Dr. Piers Ingram, Managing Director
- - Dr. Jerome Boyd-Kirkup, Chief Scientific Officer
- - Dr. Naomi Hunder, Chief Medical Officer
- - Dr. Angèle Maki, General Manager
Adam Simpson, Chairman of Callio Therapeutics and Venture Partner at Frazier Life Sciences, highlighted the urgent medical need addressed by their multi-payload ADCs, as they aim to surpass the limitations faced by current ADC therapies. He is optimistic that Callio Therapeutics, alongside its innovative technology and expert team, will lead the way in demonstrating the clinical benefits of this novel multi-payload ADC approach, potentially revolutionizing cancer treatment.
About Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is dedicated to fulfilling the potential of multi-payload antibody-drug conjugates to improve cancer therapy outcomes. The company’s leading program is a dual payload ADC targeting HER2. Established by Frazier Life Sciences, a prominent investment firm focused on innovative therapeutics based on ADC technology, Callio Therapeutics stands at the forefront of cancer treatment advancements.
For more information on Callio Therapeutics, visit their website at www.calliotx.com and follow them on LinkedIn.
About Frazier Life Sciences
Frazier Life Sciences is devoted to investing globally in both private and public companies that explore, develop, and market innovative biopharmaceuticals. Managing over $3.9 billion in capital, Frazier Life Sciences has seen more than 60 of its portfolio companies successfully complete public offerings or mergers since 2005.
About Hummingbird Bioscience
Based in Singapore, Hummingbird Bioscience operates at the intersection of artificial intelligence and human ingenuity, devoted to discovering and developing innovative therapeutics for difficult-to-treat conditions. Committed to scientific rigor, teamwork, and intellectual integrity, Hummingbird employs computational and systems biology technologies to produce a pipeline of groundbreaking monoclonal antibodies and ADCs for oncology and autoimmune diseases.
For more details on Hummingbird Bioscience, visit www.hummingbirdbioscience.com, and follow them on LinkedIn, X (formerly Twitter), and YouTube.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.